CDCA2

Cell division cycle-associated protein 2 · Q69YH5 · CDCA2 on Sugi Atlas →

0 patent compounds predicted against CDCA2, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to CDCA2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
Abemaciclib With or Without Atezolizumab for mCRPC PHASE2COMPLETED
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE) PHASE1/PHASE2NOT_YET_RECRUITING
A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation PHASE2ACTIVE_NOT_RECRUITING
Peptide Vaccine Focusing on Prevention of the Recurrence for Bladder Cancer PHASE2UNKNOWN
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma PHASE1/PHASE2RECRUITING
Genetic Changes in Patients With Non-Small Cell Lung Cancer Who Are Receiving Vinorelbine and Gemcitabine Before Surgery PHASE2COMPLETED
INCB018424 in Patients With Advanced Hematologic Malignancies PHASE2COMPLETED
Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and AMD3100 PHASE1/PHASE2COMPLETED
Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer PHASE2COMPLETED
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
A Clinical Study of TQB3824 in Subjects With Advanced Cancer PHASE1UNKNOWN
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
Peptide Vaccine Targeting to Cancer Specific Antigen Combined With Anti-angiogenic Peptide Antigen in Treating Patients With Non-small Cell Lung Cancer PHASE1COMPLETED
Phase I Study to Assess the Safety, Pharmacokinetics, & Pharmacodynamics of GSK923295 in Subjects w/ Refractory Cancer PHASE1COMPLETED
Novel Peptide Vaccination for Patients With Advanced Bladder Cancer PHASE1COMPLETED
Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel PHASE1COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Study of ABT-751 in Patients With Refractory Hematologic Malignancies PHASE1COMPLETED
Role of ADA SNPs in Subjects With Relapsing Multiple Sclerosis (RMS) nanUNKNOWN
Role of Geminin and Mcm-2 in Prognosis of Renal Cell Carcinoma nanUNKNOWN
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
The Relation of Microtubule-Associated Protein 2 and Cell Migration nanUNKNOWN
Better Delineation of CDK13 Related Phenotype and Epigenetic Signature. nanUNKNOWN
Study of the Effect of Innate on the Inflammatory Response to Endotoxin nanRECRUITING
Genetics of Primary Ciliary Dyskinesia nanCOMPLETED
PCD New Gene Discovery nanCOMPLETED
Observational Study in Patients With Cyclin-dependent Kinase-like 5 Deficiency Disorder nanACTIVE_NOT_RECRUITING
Genetic Analysis of Familial Melanoma nanCOMPLETED
Markers for Breast Cancer nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CDCA2 binder may also engage these)

ProteinNameSimilarity
MKI67 Proliferation marker protein Ki-67 1.000 landscape →
Q14B71 1.000 Q14B71 →
Q949U2 0.999 Q949U2 →
Q28DZ0 0.999 Q28DZ0 →
B4IH30 0.999 B4IH30 →
Q6KAQ7 0.999 Q6KAQ7 →
E1BC15 0.998 E1BC15 →
A0JM83 0.998 A0JM83 →
Q4QY64 0.998 Q4QY64 →
ATAD5 ATPase family AAA domain-containing protein 5 0.997 landscape →
Q86XD8 0.997 Q86XD8 →
Q4V7J0 0.997 Q4V7J0 →
Q569L8 0.997 Q569L8 →
Q8L7I1 0.997 Q8L7I1 →
Q9D9W6 0.997 Q9D9W6 →
A0A1S4GMU2 0.997 A0A1S4GMU2 →
Q9ULD2 0.996 Q9ULD2 →
Q4KLP8 0.996 Q4KLP8 →
Q5RD08 0.996 Q5RD08 →
Q9UHV7 0.996 Q9UHV7 →
P52551 0.996 P52551 →
Q3V0A6 0.996 Q3V0A6 →
E9Q5F9 0.996 E9Q5F9 →
NSD1 Histone-lysine N-methyltransferase, H3 lysine-36 specific 0.996 landscape →
Q9GSR1 0.995 Q9GSR1 →
Q86UW6 0.995 Q86UW6 →
Q7SZL5 0.995 Q7SZL5 →
Q703I1 0.995 Q703I1 →
A6NKB5 0.995 A6NKB5 →
Q5VWN6 0.995 Q5VWN6 →